Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center, Prospective Study to Evaluate the Efficacy and Safety of the Salvage Cytotoxic Regimen with Bendamustine and Brentuximab Vedotin in Patients with Refractory or Relapsed Classical Hodgkin Lymphoma

Next Previous
Trial Profile

A Single Center, Prospective Study to Evaluate the Efficacy and Safety of the Salvage Cytotoxic Regimen with Bendamustine and Brentuximab Vedotin in Patients with Refractory or Relapsed Classical Hodgkin Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 24 Jul 2018 New trial record
  • 17 Jun 2018 According to results presented at the 23rd Congress of the European Haematology Association, patients with relapsed or refractory classical hodgkin lymphoma from September 2013 to November 2017 were enrolled in this study.
  • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top